Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Plus Therapeutics filings document the company’s CNS oncology pipeline, diagnostic commercialization and public-company governance. Recent Form 8-K disclosures cover REYOBIQ regulatory developments, financial results, executive appointments and compensatory arrangements, board composition, annual meeting mechanics and Nasdaq listing matters.
The filing record also describes capital-structure actions, including the company’s reverse stock split and related charter amendment, as well as proxy disclosures on director elections, shareholder proposals, executive compensation and governance procedures. These filings connect Plus Therapeutics’ radiopharmaceutical development, CNSide diagnostic business, common stock structure and risk-related corporate events within its SEC reporting framework.
Plus Therapeutics entered an Equity Distribution Agreement that permits it to sell up to $17,350,000 of common stock through an at-the-market offering with Canaccord Genuity as sales agent.
Shares will be sold from time to time under a Form S-3 shelf registration, with Canaccord earning a 3.0% commission on gross proceeds plus up to $75,000 of reimbursed expenses. Plus Therapeutics can choose when and if to sell, set minimum acceptable prices, and suspend or terminate the program. Net proceeds are intended for general corporate purposes and working capital.
Plus Therapeutics, Inc. filed a Pre-Effective Amendment No. 1 to its Registration Statement (File No. 333-296411) on June 5, 2026 to furnish a Form of Indenture as Exhibit 4.3. The amendment is exhibits-only; the prospectus, prospectus supplement and other parts of the registration statement remain unchanged.
Plus Therapeutics, Inc. registered up to $100,000,000 of securities on a shelf registration, including an $17,350,000 at-the-market equity program under an Equity Distribution Agreement with Canaccord Genuity LLC dated June 1, 2026.
The prospectus describes a broad shelf for common stock, preferred stock, warrants, debt securities, subscription rights and units to be offered from time to time, and a separate prospectus supplement governs the ATM sales through Canaccord. The base prospectus states that proceeds use is for general corporate purposes and that specific terms and underwriting arrangements will appear in any prospectus supplement.
van Es-Johansson An reported acquisition or exercise transactions in this Form 4 filing.
PLUS THERAPEUTICS director An van Es-Johansson received new equity awards. On May 14, 2026, the director was granted options to buy 3,686 shares of common stock at $5.76 per share, expiring on May 14, 2036, vesting monthly over 12 months or fully at the 2027 Annual Stockholder Meeting. The director also received 3,686 restricted stock units, each representing one share, vesting in four equal quarterly installments starting July 1, 2026.
Plus Therapeutics director Richard J. Hawkins received new equity awards on May 14, 2026. He was granted stock options for 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. He also received 3,686 Restricted Stock Units, each representing one share of common stock.
The RSUs vest in four equal quarterly installments starting on July 1, 2026. The options vest in substantially equal monthly increments over 12 months, and are scheduled to be fully vested at the company’s 2027 Annual Stockholder Meeting, subject to his continued service.
Plus Therapeutics director Kyle Guse reported receiving new equity compensation awards. He was granted stock options covering 3,686 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest monthly over 12 months and will vest in full at the company’s 2027 Annual Stockholder Meeting, subject to continued service.
He was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of Common Stock. The RSUs vest in four equal quarterly installments, starting with one-quarter vesting on July 1, 2026, with the remainder vesting quarterly thereafter. The filing shows no open-market buys or sells, only grants classified as acquisitions.
PLUS THERAPEUTICS, INC. director Howard Clowes reported new equity-based compensation awards. He received a stock option covering 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest in substantially equal monthly installments over 12 months and vest in full at the company’s 2027 annual stockholder meeting if he continues serving through each vesting date.
Clowes was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of common stock. The RSUs vest in four substantially equal quarterly installments, with one-quarter vesting on July 1, 2026 and the remainder vesting quarterly thereafter, subject to continued service. These are non-cash, compensation-related acquisitions rather than open-market share purchases or sales.
PLUS THERAPEUTICS, INC. director Ronald Asbury Andrews reported new equity compensation awards, not open‑market trades. He received stock options for 1,600 shares of Common Stock at an exercise price of $5.76 per share, expiring on May 14, 2036, and an additional option for 3,686 shares at the same exercise price and expiration date.
He also received 3,686 Restricted Stock Units, each representing one share of Common Stock. According to the footnotes, the RSUs vest in four equal quarterly installments starting on July 1, 2026, while one option grant vests monthly over 12 months (with full vesting by the company’s 2027 Annual Stockholder Meeting) and the other vests monthly over 24 months.
PLUS THERAPEUTICS, INC. reported that its Chief Financial Officer, Andrew John Hugh MacIntyre, received new equity awards. He was granted stock options for 3,443 shares of Common Stock at an exercise price of $5.7600 per share, expiring on May 14, 2036. These options vest in substantially equal 1/48th monthly installments over four years and also vest on a change of control as described in his employment agreement.
He also received 3,443 Restricted Stock Units, each representing a right to receive one share of Common Stock. The RSUs vest ratably in 1/12th increments over twelve quarters, starting July 1, 2026, with the remainder vesting quarterly, and his total RSU holdings increased to 30,055 units after this grant.